Onderneming Foamix Pharmaceuticals Ltd. Nasdaq
Aandelen
IL0011334385
Farmaceutische producten
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 01-03-20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-03-20 |
Mutya Harsch
LAW | General Counsel | 50 | 01-03-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 10-09-20 |
Steven Basta
BRD | Director/Board Member | 59 | 01-01-15 |
Anthony Bruno
BRD | Director/Board Member | 68 | 01-03-20 |
Director/Board Member | 62 | 01-03-19 | |
David Domzalski
CEO | Chief Executive Officer | 58 | 01-03-20 |
Director/Board Member | - | 01/01 | |
Sharon Barbari
BRD | Director/Board Member | 70 | 01-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 14 098 888 | 12 874 235 ( 91,31 %) | 0 | 91,31 % |
Bedrijfsgegevens
VYNE Therapeutics, Inc.
685 Route 202/206 North Suite 301
08807, Bridgewater
+
http://www.vynetherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,08% | 681 mld. | |
+21,85% | 556 mld. | |
-4,77% | 361 mld. | |
+16,97% | 325 mld. | |
+5,69% | 285 mld. | |
+13,68% | 235 mld. | |
+3,65% | 199 mld. | |
-11,12% | 189 mld. | |
-3,40% | 157 mld. |